Global Pancreatic Cancer Drugs Market Report 2022 - Featuring Pfizer, Novartis and Amgen Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Pancreatic Cancer Drugs Global Market Report 2022, Type, End User, Drugs" report has been added to ResearchAndMarkets.com's offering.

This report provides strategists, marketers and senior management with the critical information they need to assess the global pancreatic cancer drugs market as it emerges from the COVID-19 shut down.

The global pancreatic cancer drugs market is expected to grow from $3.45 billion in 2021 to $3.71 billion in 2022 at a compound annual growth rate (CAGR) of 7.5%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $4.67 billion in 2026 at a CAGR of 5.9%.

Companies Mentioned

• Eli Lilly and Company
• F. Hoffmann-La Roche
• CLOVIS ONCOLOGY
• Pfizer
• Novartis AG
• Amgen
• Celegene Corporation
• AB Science
• GlaxoSmithKline
• Abbvie Inc.
• Medinova
• Vital Nutrients
• Threshold Pharmaceuticals
• Teva Pharmaceuticals
• Merck and Company
• PharmaCyte Biotech
• Shire
• Astellas
• Astra Zeneca
• Ipsen
• Janssen
• Nucana
• Eleison Pharmaceuticals
• Infinity Pharmaceuticals
• Genentech

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis

The pancreatic cancer drugs market consists of sales of drugs used to treat pancreatic cancer. Pancreatic cancer is a disease caused by the unrestrained growth of cells in the pancreas, thus disrupting the production of digestive juices and hormones responsible to regulate the blood sugar level in the body. This abnormal growth of cells leads to tissue lumps referred as tumors. The presence of tumors hinders the normal pancreas functioning.

The main types of pancreatic cancer drugs are endocrine pancreatic cancer and exocrine pancreatic cancer. A pancreatic cell which generates enzymes that are released into the small intestine is known as an exocrine pancreatic cell. These enzymes aid in the digestion of food as it moves through the digestive tract. The different types of drugs include afinitor, erlotinib, hydrochloride everolimus, 5-fu, flurouracil, gemcitanine, abraxane and is used in various sectors such as hospitals, clinics, others.

North America is the largest region in the pancreatic cancer drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The increasing prevalence of pancreatic cancer is expected to drive the growth of the pancreatic cancer drugs market. With the rise in number of pancreatic cancer cases, the demand for drugs is expected to increase as well, which will drive the growth of the market. The number of cancer cases have increased mainly due to ageing population and increase in number of people suffering from obesity. For instance, according to the American Cancer Society, in 2021, around 60,430 people (28,480 women and 31,950 men) are diagnosed with pancreatic cancer and approximately 48,220 people (22,950 women and 25,270 men) died from this cancer.

One of the major restraints of the pancreatic cancer drugs market is the inadequacy of results given by the drugs at the time of treatment. The inadequacy in the result is due to aggressive nature of the pancreatic cancer as the cancer cells break away from main tumor and enters into blood stream, spreading the cancer cells throughout the body in a short period of time therefore this cancer is usually discovered late. The late discovery of pancreatic cancer affects the efficacy of the drugs because the drugs can work effectively only if cancer is detected timely in an early stage itself (In the stage 1 or stage 2 where cancer cells are limited to where the tumor is present). Therefore, the mortality rate for pancreatic cancer is very high. For instance, in April 2019, in Japan out of the total number of people diagnosed for pancreatic cancer, only 5-10% survived.

For more information about this report visit https://www.researchandmarkets.com/r/gslhc9